Salvina Maria de Campos-Carli1, Aline Silva Miranda2, Ingrid Caroline Silva Dias3, Amanda de Oliveira4, Breno Fiuza Cruz5, Érica Leandro Marciano Vieira3, Natalia Pessoa Rocha6, Izabela Guimarães Barbosa3, João Vinícius Salgado7, Antônio Lúcio Teixeira8. 1. Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Av. Prof. Alfredo Balena, 190, Sala 281, Belo Horizonte, MG 30130-100, Brazil; Programa de Pós-graduação em Neurociências, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antonio Carlos, 6627, Pampulha, Belo Horizonte, MG 31270-901, Brazil. 2. Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Av. Prof. Alfredo Balena, 190, Sala 281, Belo Horizonte, MG 30130-100, Brazil; Departamento de Morfologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antonio Carlos, 6627, Pampulha, Belo Horizonte, MG 31270-901, Brazil. 3. Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Av. Prof. Alfredo Balena, 190, Sala 281, Belo Horizonte, MG 30130-100, Brazil. 4. Instituto Raul Soares, Fundação Hospitalar do Estado de Minas Gerais (FHEMIG), Av. do Contorno, 3017, Santa Efigênia, Belo Horizonte, MG 30110-080, Brazil. 5. Programa de Pós-graduação em Neurociências, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antonio Carlos, 6627, Pampulha, Belo Horizonte, MG 31270-901, Brazil. 6. Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Av. Prof. Alfredo Balena, 190, Sala 281, Belo Horizonte, MG 30130-100, Brazil; Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, 1941 East Road, Houston, TX 77054, USA. 7. Programa de Pós-graduação em Neurociências, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antonio Carlos, 6627, Pampulha, Belo Horizonte, MG 31270-901, Brazil; Departamento de Morfologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antonio Carlos, 6627, Pampulha, Belo Horizonte, MG 31270-901, Brazil; Instituto Raul Soares, Fundação Hospitalar do Estado de Minas Gerais (FHEMIG), Av. do Contorno, 3017, Santa Efigênia, Belo Horizonte, MG 30110-080, Brazil. 8. Laboratório Interdisciplinar de Investigação Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Av. Prof. Alfredo Balena, 190, Sala 281, Belo Horizonte, MG 30130-100, Brazil; Programa de Pós-graduação em Neurociências, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Presidente Antonio Carlos, 6627, Pampulha, Belo Horizonte, MG 31270-901, Brazil; Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, 1941 East Road, Houston, TX 77054, USA. Electronic address: Antonio.L.Teixeira@uth.tmc.edu.
Abstract
OBJECTIVE: Changes in immune system have been reported in schizophrenia. This study aimed to evaluate the involvement of IL-33, a member of the IL-1 cytokine family, in schizophrenia and its association with cognitive performance in these patients. METHODS: Forty patients with chronic schizophrenia and 40 healthy subjects participated in the study. Serum levels of IL-33 and sST2 (soluble form of the IL-33 receptor) were measured using enzyme-linked immunosorbent assay (ELISA). Patients were evaluated with the Brief Assessment of Cognition in Schizophrenia (BACS) and the Schizophrenia Cognition Rating Scale (SCoRS). RESULTS: Patients with schizophrenia and controls presented similar serum levels of IL-33 and sST2. Levels of both markers were positively correlated with cognitive performance in patients with schizophrenia. CONCLUSION: We found a significant correlation between IL-33 and sST2 levels and cognition in schizophrenia. Our results might help in the understanding of how immune markers are associated with cognitive impairment in schizophrenia. It remains to be determined whether the association between IL-33/sST2 and cognition is restricted to patients with schizophrenia.
OBJECTIVE: Changes in immune system have been reported in schizophrenia. This study aimed to evaluate the involvement of IL-33, a member of the IL-1 cytokine family, in schizophrenia and its association with cognitive performance in these patients. METHODS: Forty patients with chronic schizophrenia and 40 healthy subjects participated in the study. Serum levels of IL-33 and sST2 (soluble form of the IL-33 receptor) were measured using enzyme-linked immunosorbent assay (ELISA). Patients were evaluated with the Brief Assessment of Cognition in Schizophrenia (BACS) and the Schizophrenia Cognition Rating Scale (SCoRS). RESULTS:Patients with schizophrenia and controls presented similar serum levels of IL-33 and sST2. Levels of both markers were positively correlated with cognitive performance in patients with schizophrenia. CONCLUSION: We found a significant correlation between IL-33 and sST2 levels and cognition in schizophrenia. Our results might help in the understanding of how immune markers are associated with cognitive impairment in schizophrenia. It remains to be determined whether the association between IL-33/sST2 and cognition is restricted to patients with schizophrenia.
Authors: M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker Journal: Mol Psychiatry Date: 2022-04-28 Impact factor: 15.992
Authors: Milica M Borovcanin; Slavica M Janicijevic; Ivan P Jovanovic; Nevena Gajovic; Nebojsa N Arsenijevic; Miodrag L Lukic Journal: Front Psychiatry Date: 2018-06-22 Impact factor: 4.157
Authors: Gianluca Pandolfo; Giovanni Genovese; Marco Casciaro; Maria Rosaria Anna Muscatello; Antonio Bruno; Giovanni Pioggia; Sebastiano Gangemi Journal: Medicina (Kaunas) Date: 2021-03-26 Impact factor: 2.430